Turn this list into pipeline.
Biotech Companies in Reading: 31 Active Firms (2026)
Biotech companies in Reading develop life-science technologies, therapeutics and diagnostics within the local metropolitan area.
R&D, clinical and market-access teams are the main buying centres, with laboratory procurement and outsourced manufacturing also shaping demand. Buyers are usually other organisations: pharmaceutical groups, healthcare providers, research institutions and specialist laboratories looking for therapeutic, diagnostic or platform-science capability rather than general software or equipment supply. Engagements tend to be specialist and staged, moving from feasibility work and assay validation into clinical, regulatory or licensing discussions. Firms in this part of the market are typically small to mid-sized operators with lean internal teams and external research, clinical or manufacturing partners.
Read more
Reading has 31 trading biotech companies, making it a compact local market rather than a broad regional cluster. Reported headcount across the cohort is 219, which points to specialist teams rather than large integrated research campuses. The local picture fits a metropolitan life-sciences pattern: small commercial and research-led firms serving pharmaceutical, healthcare, laboratory and research customers, often with outsourced clinical, research or manufacturing capacity rather than fully internal operations.
Medicines and diagnostics activity around Reading sits inside the UK life-sciences rulebook rather than a local licensing regime. The MHRA sets standards, evaluates new treatments, approves clinical trial applications, assesses marketing authorisations and oversees post-authorisation safety monitoring through pharmacovigilance. Clinical trials also bring Good Clinical Practice, ethics review and informed-consent requirements into commercial planning. Market access can add a further test where health technology assessment by NICE informs routine NHS use. The BioIndustry Association and ABPI give the sector organised representation, but regulatory burden still varies by activity: discovery tools, diagnostics and therapeutic assets face different evidence expectations.
Reading’s biotech pipeline appears more likely to deepen through specialist discovery, diagnostic and translational niches than through a broad set of fully integrated developers. Scale-up scarcity tends to matter: lean teams can move early research forward, but clinical evidence, pharmacovigilance and market-access work raise the cost and governance load before sales become routine. Partnerships with pharmaceutical, healthcare, laboratory and research customers are likely to remain central. Consolidation also looks plausible where owners need regulatory capacity, manufacturing access or commercial routes that are difficult to build inside a small local business.
31
Active firms
2026
5
Above £5M
reported turnover
2
New since 2022
incorporations
Key facts
About 16% of the trading cohort reports turnover above £5M (5 of 31 firms) — the rest sits below that revenue band.
6% of the cohort was incorporated since 2022 (2 firms), so a sizeable share is in its first few filing cycles.
The MHRA approves clinical trial applications, assesses marketing authorisations or drug licences, and monitors post-authorisation safety through pharmacovigilance.
Clinical trials must follow Good Clinical Practice, ethics review and informed-consent requirements; approved medicines may also be reviewed by NICE before routine NHS use.
The UK life-sciences industry comprised 6,170 businesses across 7,320 companies in 2023/2024, employing 359,600 people and generating £146.9 billion in turnover.
The biopharmaceutical subsector generated £98.9 billion in turnover across 2,960 companies in 2023/2024, accounting for 67% of total life-sciences turnover.
UK biotech raised £3.5 billion in equity investment in 2024, a 94% increase on 2023, with financing concentrated in a small number of large rounds, mainly from US investors.
Top Reading biotech companies
Clasado Biosciences
Develops and supplies prebiotic ingredients, including the galactooligosaccharide product Bimuno® GOS, for use in dietary supplements, functional foods and beverages. Conducts microbiome and gut…
Serves B2B nutrition and consumer health brands developing supplements, synbiotics, ready-to-drink beverages, functional foods, foods for special medical purposes, sports nutrition and pet nutrition…
Location
Clasado Biosciences
Develops and supplies prebiotic ingredients for use in dietary supplements, functional foods, beverages and pet nutrition products. Conducts microbiome research and supports partners with formulation…
Serves B2B health, nutrition and food brands developing gut-health products, including supplement, synbiotic, ready-to-drink beverage, functional food, FSMP, sports nutrition and pet nutrition…
Location
CRO Solutions Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides contract research services for clinical trials, including clinical project management, protocol writing, site monitoring, data management, pharmacovigilance, biostatistics, medical writing,…
Serves biotech and pharmaceutical companies, particularly clinical operations and research teams running early-phase clinical trials and drug development studies.
Financial Health
WeakWeak · -13% CAGR over 2y
Location
Novai Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops DARC (Detection of Apoptosing Retinal Cells) imaging technology and AI analysis tools for early detection of retinal cell death and neurodegenerative eye and brain diseases, supporting…
Serves patients with eye and brain disease concerns, clinicians and healthcare professionals selecting treatments, and pharmaceutical companies running ophthalmic preclinical research and clinical…
Financial Health
DistressedDistressed · -12% CAGR over 2y
Location
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops and manufactures treatments for respiratory allergies, including allergy immunotherapy vaccines, diagnostic products, and emergency medicines such as adrenaline sprays, and conducts research…
Serves consumers with allergies and healthcare professionals and organisations managing respiratory allergy, allergic asthma and anaphylaxis.
Financial Health
HealthyHealthy · 5% CAGR over 1y
Location
Sarepta International UK Ltd.
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsDevelops precision genetic medicines for rare neuromuscular and central nervous system diseases. Conducts biotechnology research and drug development using gene therapy, RNA‑targeted exon skipping…
Serves patients with rare neuromuscular and central nervous system diseases, plus health networks, clinicians and payers involved in access to genetic medicines.
Financial Health
HealthyHealthy · Hiring · 5% CAGR over 2y
Location
Oxford Immune Algorithmics Ltd
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops AI‑based medical technology that analyses blood and immune system data over time to detect disease patterns and health changes. Provides a mobile monitoring system integrating wearable…
Serves healthcare providers and patients, especially in oncology and chronic disease monitoring. Targets clinicians, hospitals and home-monitored patients needing continuous remote immune monitoring,…
Financial Health
StrongStrong · Growing, Hiring · 52% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies minimally invasive cardiac implants and related accessories used in interventional cardiology, including occluder devices for closing heart defects such as PFO, ASD and PDA, and…
Sells B2B to hospitals, cardiac centres and interventional cardiology teams treating adult structural heart defects, congenital heart disease and heart failure, supported by distributors and sales…
Financial Health
HealthyHealthy · Hiring · 3% CAGR over 4y
Location
Develops and supplies modular spinal implant systems used in spinal surgery to restore and maintain spinal alignment. Products include interbody cages and instrumentation designed for controlled…
Serves spine surgeons, hospitals and surgical teams involved in spinal fusion procedures, with its market currently focused on the USA where sale is approved.
Financial Health
Insufficient historyInsufficient history
Location
GENERAL BIOINFORMATICS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides bioinformatics services for scientific research, including data capture, curation and analysis of biological datasets. Supports research projects by developing analytical workflows and…
Serves life sciences research organisations, academic or institutional science teams, and R&D groups working with biological data, especially outside human-genome drug discovery and in non-model…
Financial Health
WeakWeak · -2% CAGR over 4y
Location
Senechaem Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · 0% CAGR over 4y
Location
APACOR LIMITED
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops and manufactures in vitro diagnostic products for laboratories, including tests and reagents for medical parasitology, rapid diagnostic kits, electrophoresis consumables, environmental…
Sells to laboratories worldwide and business partners in medical diagnostics, including parasitology, rapid testing and pathology. Also serves OEM and channel partners involved in in vitro…
Financial Health
WeakWeak · 6% CAGR over 1y
Location
CHAIN Biotech
Trajectory
4y · 2020–NowFinancial sub-scores
Computed from 4 filingsDevelops microbiome-based therapeutics including oral vaccines and immunotherapies targeting the lower gastrointestinal tract. Uses a Clostridium-based drug delivery platform to engineer bacteria…
Serves pharmaceutical and biotechnology partners, oncology research organisations and clinical development collaborators in gastrointestinal and immune-oncology therapeutics.
Financial Health
StableStable · Hiring · 2% CAGR over 5y
Location
BIOQPHARMA CONSULTANCY LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops drug delivery systems for infusible medicines using its patented invenious platform. Produces pre‑filled, ready‑to‑use “connect‑and‑go” infusion products and partners with pharmaceutical…
Serves pharmaceutical manufacturers and commercial partners in the infusible medicines market, alongside healthcare providers, payers and patients involved in infusion-based care.
Financial Health
HealthyHealthy · Growing · 0% CAGR over 4y
Location
Oxford Expression Technologies
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies baculovirus-based protein expression systems, including flashBAC kits, vectors, insect cells and culture media. Provides contract services such as vector design, recombinant…
Serves pharmaceutical and biotechnology companies worldwide, including research and development teams working on protein expression, vaccine, diagnostic and gene therapy applications.
Financial Health
StableStable · 0% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides contract research organisation services to pharmaceutical, biotechnology and medical device companies, supporting clinical trials through clinical operations, data management, statistics and…
Serves B2B clients in life sciences, primarily biotech, pharmaceutical and medical device companies needing clinical research support. Targets teams running clinical trials, drug safety, regulatory,…
Financial Health
WeakWeak
Location
Biointeractions Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures biocompatible surface coatings and biomaterials for medical devices, including antithrombogenic, antimicrobial and hydrophilic coatings designed to reduce infection,…
Serves B2B medical device manufacturers and medtech developers producing minimally invasive and implantable devices, including teams seeking biomaterial coatings for infection prevention, thrombosis…
Financial Health
HealthyHealthy · Hiring · 8% CAGR over 4y
Location
PEPCEUTICALS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies biochemical reagents and raw materials for life science and diagnostic applications, including carbohydrates, nucleosides, peptides, enzymes and antibodies. Provides custom synthesis,…
Serves B2B life sciences and diagnostics markets, including pharmaceutical and biotech companies, IVD manufacturers, research laboratories and manufacturers with GMP/CDMO supply chain needs.
Financial Health
WeakWeak · -72% CAGR over 4y
Location
Biosynth
Manufactures and supplies biochemical reagents and raw materials for life sciences and diagnostics, including carbohydrates, nucleosides, peptides, antibodies, enzymes and research chemicals.…
Sells to B2B buyers in life sciences, diagnostics and pharmaceuticals, including research labs, IVD manufacturers, biotech companies and pharma development/manufacturing teams.
Location
DIAGNOSTICA STAGO UK LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies diagnostic instruments, reagents and software for haemostasis and thrombosis testing in biomedical laboratories. Provides coagulation assays, platelet and thrombin generation analysis…
Serves biomedical, pathology and hospital laboratories, along with healthcare professionals involved in haemostasis and thrombosis testing and quality control.
Financial Health
StableStable · 2% CAGR over 4y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops biotherapeutic drugs for livestock and companion animal diseases using VHH antibody technology. Conducts antibody development, cellular assays, protein expression, purification, and…
Targets the animal health market, including veterinary pharmaceutical partners and stakeholders focused on livestock and companion animal disease treatment.
Financial Health
StrongStrong · Growing, Hiring · 84% CAGR over 5y
Location
Develops and supplies medical devices and systems used in infusion therapy, vascular access, and medication delivery. Provides products and solutions for hospitals and healthcare providers, including…
Serves public and private healthcare providers, including hospitals, labs, pharmacies, surgical teams, clinical staff, homecare and ambulatory infusion services, plus life sciences manufacturers and…
Location
A. Menarini Diagnostics
Supplies in vitro diagnostic systems, instruments and reagents for clinical laboratories and healthcare providers. Product areas include diabetes care testing, immunoassay, molecular diagnostics,…
Serves healthcare providers, clinical laboratories, hospitals, emergency and point-of-care settings, and diabetes care users, with buyers including diagnostics professionals and clinicians.
Location
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops and supplies automated sample preparation systems for chromatography used in analytical laboratories. Products include the ePrep ONE automation platform, microSPE cartridges, software and…
Serves analytical chemistry laboratories in life sciences, pharmaceuticals, environmental testing, food safety, and forensic/clinical toxicology, especially regulated labs needing compliant…
Financial Health
StableStable · 0% CAGR over 1y
Location
Emalex Ltd
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsDevelops pharmaceutical treatments for central nervous system disorders, with a focus on Tourette syndrome. Conducts clinical research and trials for investigational drugs, including dopamine D1…
Serves patients with Tourette syndrome and other central nervous system disorders, including paediatric and adult patients with limited approved treatment options.
Financial Health
HealthyHealthy · Growing · 0% CAGR over 4y
Location
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides purpose-built mobile devices and technology for clinical trials, including patient and site devices, global eSIM connectivity, mobile device management, and lifecycle support services for…
Sells to life sciences organisations running clinical trials, including sponsors, CROs and clinical trial technology vendors, with patient and site teams as end users across therapeutic areas and…
Financial Health
StableStable
Location
Greyrigge Associates Limited
Trajectory
3y · 2024–NowFinancial sub-scores
Computed from 3 filingsProvides consultancy services to biotechnology companies developing biologics and advanced therapies, including gene and cell therapies. Advises on CMC and manufacturing, quality assurance,…
Serves biotech and biopharma organisations, from start-ups to multinationals, developing biologics, vaccines, cell and gene therapies, plus investors and boards involved in these programmes.
Financial Health
DistressedDistressed · -87% CAGR over 2y
Location
PHARMHE (UK) LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies biological, pharmaceutical and nutritional materials, including recombinant proteins, antibodies, amino acids and vitamins. Provides R&D and material science services such as encapsulation,…
Serves B2B manufacturers and R&D teams in biological, pharmaceutical, personal care and cosmetics, food and medical nutrition sectors, including producers of infant formula and clinical nutrition…
Financial Health
StrongStrong · Growing, Hiring · 26% CAGR over 4y
Location
Hypo-Stream Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
HealthyHealthy · -7% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsSupplies implantable medical devices for orthopaedic surgery, including the iFuse Implant System used in minimally invasive sacroiliac joint fusion. Provides related surgical technologies, clinical…
Sells to orthopaedic and spine surgeons, hospitals and healthcare providers treating sacroiliac joint dysfunction, pelvic trauma and spinal deformity, with patient-facing information for people…
Financial Health
WeakWeak · -16% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
WeakWeak · 0% CAGR over 4y
Location
Unlock all 31 leads
Showing 31 of 31 — +0 more with verified decision-maker contacts, live data, and CRM sync.
How Reading biotech companies work and how to sell to them
What they do
Reading biotech companies usually earn revenue through milestone-funded research collaborations, assay or platform-access agreements, diagnostic service contracts, contract research work and out-licensing of intellectual property. Therapeutic developers may have little routine sales revenue until an asset is partnered or licensed, so commercial conversations often sit around staged proof points: feasibility, validation, preclinical evidence, clinical-readiness and market-access evidence. Diagnostic and laboratory-service firms can look more transactional, with per-test, project or service-fee pricing. Contract values tend to be shaped by evidence risk, exclusivity, territory and rights ownership rather than simple seat counts. The product is usually a scientific asset, regulated service or specialist capability, not a horizontal tool.
Who they sell to
Most buyers are pharmaceutical groups, healthcare providers, research institutions, specialist laboratories and, for some diagnostics, procurement teams inside clinical settings. The commercial sponsor may be a VP of R&D, translational medicine lead, clinical director, head of diagnostics, business-development lead or procurement manager, with finance and legal joining once rights, liability and evidence obligations are clear. Sales cycles are usually consultative and slow by software standards: early feasibility can start through scientific networks, while larger licensing, clinical or supply agreements move through diligence, contracting and governance review. Direct selling and partner-led introductions matter more than self-serve channels; formal procurement tends to appear when services touch clinical operations or public-sector purchasing.
What they buy
Most Reading biotech firms tend to spend on laboratory systems, quality management, document control, clinical trial operations, regulatory affairs support, pharmacovigilance, data management and specialist insurance. Lean teams also buy outsourced research, contract manufacturing, bioanalysis, market-access support, statistical analysis, legal advice on licensing and intellectual property, and finance support for grant, R&D tax and investor reporting. On the software side, useful categories include laboratory information management, electronic lab notebooks, sample tracking, security, customer relationship management, billing, analytics and HR systems. Sellers should expect careful scrutiny of validation, audit trails, permissions, data retention and evidence handling; a cheap generic tool can still fail if it creates regulatory or quality risk.
Why and how to sell to them
Biotech buyers tend to evaluate vendors when a programme moves from research into regulated development, when a diagnostic service approaches clinical use, when a funding round changes reporting expectations, or when a partnership creates new diligence requirements. Other triggers include leadership hires in clinical, regulatory, quality, finance or commercial roles; outsourced manufacturing plans; preparation for MHRA interaction; and the need to evidence costs, timelines and risk to partners. Outbound works better when it is specific to the operating constraint: reducing audit burden, shortening partner diligence, protecting trial data, managing outsourced work or giving small teams capacity they do not want to hire permanently. Broad productivity claims usually land poorly.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Reading
Related directories
Frequently asked questions
How many biotech companies are there in the Reading?↓
What counts as a biotech company in this list?↓
Which are the largest biotech companies in the Reading?↓
What do biotech companies in the Reading actually do?↓
How does Reading biotech compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical biotech companies in the Reading?↓
Are these mostly new or established biotech companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 31 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.